132
Participants
Start Date
July 12, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
B007
B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
RECRUITING
Peking University First Hospital, Beijing
RECRUITING
The Second Xiangya Hospital of Central South University, Changsha
RECRUITING
Chengdu Second People's Hospital, Chengdu
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
The First Affiliated Hospital of Fujian Medical University, Fuzhou
RECRUITING
Dermatology Hospital of Southern Medical University, Guangzhou
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Shandong First Medical University-Affiliated Skin Hospital, Jinan
RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Henan Provincial People's Hospital, Zhengzhou
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY
Shanghai Jiaolian Drug Research and Development Co., Ltd
INDUSTRY